Top-Rated StocksTop-Rated AbCellera Biologics Stock Price, News & Analysis (NASDAQ:ABCL) $4.87 +0.03 (+0.62%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$4.70▼$4.9750-Day Range$3.91▼$4.8552-Week Range$3.87▼$11.38Volume1.52 million shsAverage Volume2.06 million shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$20.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media AbCellera Biologics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside317.2% Upside$20.11 Price TargetShort InterestBearish13.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.48) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector450th out of 960 stocksPharmaceutical Preparations Industry162nd out of 372 stocks 4.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.11, AbCellera Biologics has a forecasted upside of 317.2% from its current price of $4.82.Amount of Analyst CoverageAbCellera Biologics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.87% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 1.22%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 1.8 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -32% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.39% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.48) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AbCellera Biologics Stock (NASDAQ:ABCL)AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesDecember 8, 2023 | seekingalpha.comAbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024December 8, 2023 | americanbankingnews.comKeyCorp Weighs in on AbCellera Biologics Inc.'s FY2023 Earnings (NASDAQ:ABCL)December 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 7, 2023 | seekingalpha.comBuy AbCellera Biologics's Revolutionizing AI-Powered Drug Development PlatformDecember 6, 2023 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Now Covered by Analysts at KeyCorpDecember 6, 2023 | americanbankingnews.comAnalysts Set AbCellera Biologics Inc. (NASDAQ:ABCL) PT at $21.88December 3, 2023 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Shares Down 3.4% December 3, 2023 | americanbankingnews.comComparing AbCellera Biologics (NASDAQ:ABCL) & Adicet Bio (NASDAQ:ACET)December 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 2, 2023 | markets.businessinsider.comLeerink Partners Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)November 30, 2023 | theglobeandmail.comAbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developerNovember 29, 2023 | theglobeandmail.comCutting-edge antibody therapy firm AbCellera to lay off 10% of work forceNovember 24, 2023 | finance.yahoo.comAbCellera Biologics Insiders Added US$2.47m Of Stock To Their HoldingsNovember 22, 2023 | morningstar.comAbCellera Biologics Inc Ordinary SharesNovember 9, 2023 | benzinga.comAbCellera Biologics Director Trades Company's StockNovember 3, 2023 | finance.yahoo.comAbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023November 3, 2023 | finance.yahoo.comAbCellera Biologics (ABCL) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | finance.yahoo.comPrelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline ProgressNovember 2, 2023 | finance.yahoo.comAbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 MillionNovember 2, 2023 | finance.yahoo.comAbCellera Reports Q3 2023 Business ResultsOctober 26, 2023 | finance.yahoo.comEarnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to DeclineOctober 16, 2023 | realmoney.thestreet.comSmall-Cap Biotech Needs Some Emergency CareOctober 13, 2023 | markets.businessinsider.comAbCellera Biologics: Promising Investment in Antibody Therapeutics Backed by Proprietary Discovery Engine and Strategic PartnershipsOctober 11, 2023 | finance.yahoo.comAbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023September 27, 2023 | benzinga.comBoard Member of AbCellera Biologics Purchased $98K In StockSeptember 25, 2023 | seekingalpha.comAbCellera's Clinical Carousel: High Risk, Higher StakesSeptember 20, 2023 | finance.yahoo.comAbCellera Expands Multi-Target Antibody Discovery Collaboration with RegeneronSee More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees630Year FoundedN/APrice Target and Rating Average Stock Price Target$20.11 High Stock Price Target$34.00 Low Stock Price Target$6.00 Potential Upside/Downside+313.0%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$158.52 million Net Margins-256.27% Pretax Margin-311.24% Return on Equity-10.72% Return on Assets-8.48% Debt Debt-to-Equity RatioN/A Current Ratio8.34 Quick Ratio8.34 Sales & Book Value Annual Sales$485.42 million Price / Sales2.91 Cash Flow$0.68 per share Price / Cash Flow7.21 Book Value$4.31 per share Price / Book1.13Miscellaneous Outstanding Shares290,170,000Free Float196,010,000Market Cap$1.41 billion OptionableNot Optionable Beta0.28 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 48)CEO, President & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 49)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 38)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 53)J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Comp: $644.4kMr. Neil Aubuchon M.B.A. (Age 53)Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 48)Chief Technology Officer Josephine Hellschlienger Ph.D.Manager of Investor RelationsMs. Tiffany Chiu B.Sc.Ph.D., Vice President of CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMore ExecutivesKey CompetitorsMaravai LifeSciencesNASDAQ:MRVIPacira BioSciencesNASDAQ:PCRXArvinasNASDAQ:ARVNAurinia PharmaceuticalsNASDAQ:AUPHAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 10,500 shares on 12/1/2023Ownership: 0.004%American Century Companies Inc.Sold 158,293 shares on 11/30/2023Ownership: 0.329%Graham Capital Management L.P.Bought 108,060 shares on 11/22/2023Ownership: 0.062%Walleye Capital LLCBought 1,000 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCSold 26,400 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ABCL Stock Analysis - Frequently Asked Questions Should I buy or sell AbCellera Biologics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks. What is AbCellera Biologics' stock price target for 2024? 11 brokerages have issued 1 year target prices for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $34.00. On average, they expect the company's stock price to reach $20.11 in the next year. This suggests a possible upside of 317.2% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts. How have ABCL shares performed in 2023? AbCellera Biologics' stock was trading at $10.13 at the start of the year. Since then, ABCL shares have decreased by 52.4% and is now trading at $4.82. View the best growth stocks for 2023 here. When is AbCellera Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our ABCL earnings forecast. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) announced its earnings results on Thursday, November, 2nd. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company earned $6.60 million during the quarter, compared to analysts' expectations of $11.92 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 10.72% and a negative net margin of 256.27%. What ETFs hold AbCellera Biologics' stock? ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ). When did AbCellera Biologics IPO? (ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.03%), Federated Hermes Inc. (1.12%), Lazard Asset Management LLC (1.08%), American Century Companies Inc. (0.33%), Royal Bank of Canada (0.14%) and Schonfeld Strategic Advisors LLC (0.12%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ABCL) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.